Mepolizumab does not alter levels of eosinophils, T cells, and mast cells in the duodenal mucosa in eosinophilic esophagitis.
Conus
Sébastien
S
Straumann
Alex
A
Bettler
Eva
E
Simon
Hans-Uwe
HU
D000328:Adult; D000911:Antibodies, Monoclonal / Q000494:pharmacology / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D004386:Duodenum / Q000473:pathology*; D004802:Eosinophilia / Q000188:drug therapy* / Q000276:immunology; D004804:Eosinophils / Q000187:drug effects*; D004941:Esophagitis / Q000188:drug therapy* / Q000276:immunology; D005260:Female; D006801:Humans; D015848:Interleukin-5 / Q000037:antagonists & inhibitors*; D007413:Intestinal Mucosa / Q000473:pathology*; D008297:Male; D008407:Mast Cells / Q000187:drug effects*; D013601:T-Lymphocytes / Q000187:drug effects*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D015848:Interleukin-5; C434107:mepolizumab